Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q8BG95
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q8BG95-F1 | Predicted | AlphaFoldDB |
50 variants for Q8BG95
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388501766 | 5 | E>K | No | EVA | |
| rs3388503040 | 12 | A>T | No | EVA | |
| rs3388500425 | 14 | S>T | No | EVA | |
| rs250381999 | 40 | G>C | No | EVA | |
| rs3388498742 | 52 | P>L | No | EVA | |
| rs3388501763 | 62 | F>S | No | EVA | |
| rs3388502933 | 169 | M>T | No | EVA | |
| rs3388500153 | 237 | I>T | No | EVA | |
| rs3388499729 | 242 | E>G | No | EVA | |
| rs3388502681 | 267 | S>F | No | EVA | |
| rs3388502648 | 290 | A>G | No | EVA | |
| rs3388503105 | 290 | A>T | No | EVA | |
| rs3388502150 | 292 | E>D* | No | EVA | |
| rs3388502525 | 292 | E>G | No | EVA | |
| rs3388500123 | 294 | L>I | No | EVA | |
| rs3388500466 | 294 | L>R | No | EVA | |
| rs864269696 | 331 | L>I | No | EVA | |
| rs30842481 | 384 | P>S | No | EVA | |
| rs3388500122 | 397 | S>N | No | EVA | |
| rs3390670353 | 400 | M>I | No | EVA | |
| rs3388501799 | 400 | M>L | No | EVA | |
| rs3390678364 | 401 | E>V | No | EVA | |
| rs3388500879 | 402 | Q>H | No | EVA | |
| rs228102744 | 418 | R>K | No | EVA | |
| rs3388502135 | 610 | E>* | No | EVA | |
| rs3388499804 | 611 | A>V | No | EVA | |
| rs3388499738 | 625 | E>* | No | EVA | |
| rs3388500478 | 642 | R>Q | No | EVA | |
| rs3388500151 | 653 | L>R | No | EVA | |
| rs3388498448 | 657 | E>G | No | EVA | |
| rs3388502168 | 663 | S>E | No | EVA | |
| rs244794039 | 665 | A>V | No | EVA | |
| rs3388499988 | 688 | K>E | No | EVA | |
| rs3388502221 | 702 | E>* | No | EVA | |
| rs30843392 | 745 | R>H | No | EVA | |
| rs30843393 | 751 | G>V | No | EVA | |
| rs30844924 | 765 | A>V | No | EVA | |
| rs260468222 | 772 | S>R | No | EVA | |
| rs3388500289 | 789 | V>I | No | EVA | |
| rs3388500487 | 872 | S>G | No | EVA | |
| rs3388500165 | 873 | N>S | No | EVA | |
| rs3388503015 | 923 | S>Y | No | EVA | |
| rs3388502077 | 925 | V>M | No | EVA | |
| rs3390586641 | 926 | L>Q | No | EVA | |
| rs3388498426 | 947 | M>V | No | EVA | |
| rs3388499710 | 956 | D>Y | No | EVA | |
| rs3388502642 | 957 | N>S | No | EVA | |
| rs3388502699 | 966 | A>V | No | EVA | |
| rs3388502169 | 975 | S>F | No | EVA | |
| rs3390663660 | 976 | K>A | No | EVA |
No associated diseases with Q8BG95
3 regional properties for Q8BG95
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| repeat | Ankyrin repeat | 56 - 155 | IPR002110-1 |
| repeat | Ankyrin repeat | 209 - 281 | IPR002110-2 |
| domain | cGMP-dependent protein kinase, interacting domain | 875 - 976 | IPR031775 |
4 GO annotations of cellular component
| Name | Definition |
|---|---|
| A band | The dark-staining region of a sarcomere, in which myosin thick filaments are present; the center is traversed by the paler H zone, which in turn contains the M line. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytoskeleton | A cellular structure that forms the internal framework of eukaryotic and prokaryotic cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles. |
| Z disc | Platelike region of a muscle sarcomere to which the plus ends of actin filaments are attached. |
3 GO annotations of molecular function
| Name | Definition |
|---|---|
| enzyme inhibitor activity | Binds to and stops, prevents or reduces the activity of an enzyme. |
| phosphatase regulator activity | Binds to and modulates the activity of a phosphatase, an enzyme which catalyzes of the removal of a phosphate group from a substrate molecule. |
| protein kinase binding | Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. |
1 GO annotations of biological process
| Name | Definition |
|---|---|
| signal transduction | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. |
3 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9BZL4 | PPP1R12C | Protein phosphatase 1 regulatory subunit 12C | Homo sapiens (Human) | PR |
| Q96T49 | PPP1R16B | Protein phosphatase 1 regulatory inhibitor subunit 16B | Homo sapiens (Human) | PR |
| O60237 | PPP1R12B | Protein phosphatase 1 regulatory subunit 12B | Homo sapiens (Human) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAELEHLGGK | RAESARARRA | EQLRRWRGSL | TEQEPAERQG | AGRQLQTRRG | SPRVRFEDGA |
| 70 | 80 | 90 | 100 | 110 | 120 |
| VFLAACSSGD | TDEVKKLLAR | GADINTVNVD | GLTALHQACI | DENLDMVKFL | VENRANVNQQ |
| 130 | 140 | 150 | 160 | 170 | 180 |
| DNEGWTPLHA | AASCGYLNIA | EYFISHGASV | GIVNSEGEVP | SDLAEEPAMK | DLLLEQVKKQ |
| 190 | 200 | 210 | 220 | 230 | 240 |
| GVDLEQSRKE | EEQQMLQDAR | QWLNSGRIED | VRQARSGATA | LHVAAAKGYS | EVLRLLIQAG |
| 250 | 260 | 270 | 280 | 290 | 300 |
| YELNVQDHDG | WTPLHAAAHW | GVKEACSILA | EALCDMDIRN | KLGQTPFDVA | DEGLVEHLEM |
| 310 | 320 | 330 | 340 | 350 | 360 |
| LQKKQDVLRS | EKETRNKLIE | SDLNSKFQSG | LFKNKEKMLY | EEEIPKSQDT | EEENKESSSS |
| 370 | 380 | 390 | 400 | 410 | 420 |
| SSEEEEGEDE | VSESETEKEA | DKKPEATVNH | SNSEIKSRIM | EQIPAPAQNT | FSASSARRLS |
| 430 | 440 | 450 | 460 | 470 | 480 |
| SLFNKAEEPK | DESPSSWRLG | LRKTGSHNML | SEVANSREAL | RDRGSSIYRS | SSSPRISALL |
| 490 | 500 | 510 | 520 | 530 | 540 |
| DDKDKERENK | SYFSMLVPRR | LSSTSDIEEK | ENRESAVNLV | RSGSHTRQLW | RDEAKGSETP |
| 550 | 560 | 570 | 580 | 590 | 600 |
| QTIAPSTYTS | TYLKRTPYKS | QADSTAEKTA | DSVSSSTPLC | VITNRPAPST | ANGVPAATVF |
| 610 | 620 | 630 | 640 | 650 | 660 |
| SSAGTDPSVE | AREKRRSYLT | PVRDEEAESL | RKARSRQARQ | TRRSTQGVTL | TDLQEAEKTF |
| 670 | 680 | 690 | 700 | 710 | 720 |
| SRSRAERQAQ | EQPGEKLEDP | GGLEGSTKKQ | EPSAAPTKGA | GEGRSLEEEP | IYHRLRYPTQ |
| 730 | 740 | 750 | 760 | 770 | 780 |
| PDKPTTPVSP | SASRPSLYTG | SHLLRTSRAS | GPDSENSETS | THATAAKEMD | TSEKGEADLD |
| 790 | 800 | 810 | 820 | 830 | 840 |
| DQSSNRLSVR | ERRRAKDRRR | GTGINFWTND | EDETDVSEEV | KEALHERLSR | LESGGTNPTS |
| 850 | 860 | 870 | 880 | 890 | 900 |
| SDSYSDRASA | RARREAREAR | LASLTSRVEE | DSNRDYKKLY | ESALTENQKL | KTKLQEAQLE |
| 910 | 920 | 930 | 940 | 950 | 960 |
| LADIKAKLEK | MAQQKQEKTS | DRSSVLEVEK | RERRALERKM | SEMEEEMKVL | TELKSDNQRL |
| 970 | |||||
| KDENGALIRV | ISKLSK |